CHMP negative opinion leaves cash-strapped Santhera fighting the orphan data battle
This article was originally published in Scrip
Executive Summary
The future looks uncertain for Santhera Pharmaceuticals as the European Medicines Agency's Committee for Medicinal Products for Human Use has narrowly decided to recommend against approval of the Swiss firm's idebenone for the treatment of the rare genetic disease Leber's hereditary optic neuropathy (LHON).
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi’s New Loan Offers Win-Win Model For Pharma And Society
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Need a specific report? 1000+ reports available
Buy Reports